HUYA Bioscience International expands HBI-8000 clinical trials for breast cancer

[News]

HUYA Bioscience International (HUYA) today announced expanding clinical trials with its lead cancer drug, HBI-8000, starting with a Phase 1 combination trial in support of a breast cancer program to be conducted in the United States.

More... (http://www.news-medical.net/news/20150903/HUYA-Bioscience-International-expands-HBI-8000-clinical-trials-for-breast-cancer.aspx)